Outlicensing deals among Chinese biotech firms are setting off speculation about which will first bring their own branded drugs to global markets . Analysts think within 10 to 15 years,some could crack Europe and the U.S.
Outlicensing lets companies give others exclusive rights to develop, manufacture,market early-stage drugs. This setup often involves upfront cash, milestone payments,and royalties on future sales. Profits can be huge, especially in overseas markets where pharma demand is high.
The U.S. is the world's most lucrative drug market,though it holds less than 5% of global population. American patients and insurers frequently pay more for same drugs than elsewhere. This pricing strategy means U.S. accounts for about three-quarters of global pharma profits.
As international drug sales shift,watching Chinese biotech firms becomes crucial. Investors,experts are watching closely,trying to spot which will seize chance to make a mark globally . But which will succeed…?
